Penumbra, Inc. (PEN)

Penumbra's stock has been impacted by Boston Scientific's acquisition announcement, earnings reports, stock performance, analyst rating changes, and insider selling. Boston Scientific announced its intent to acquire Penumbra in January 2026, which was approved by Penumbra shareholders in May 2026. Penumbra reported mixed Q1 2026 earnings, surpassing revenue expectations but missing EPS estimates. Analyst ratings have been adjusted by various firms, and insiders have sold shares of the company's stock.

Information regarding the specific demand seasonality for Penumbra, Inc.'s products and services is not directly available in the provided search results.

Penumbra, Inc. is a global healthcare company specializing in innovative medical devices for neurovascular and peripheral vascular conditions. Their product portfolio includes mechanical thrombectomy platforms, embolization coil systems, access products, neurosurgical tools, and other technologies like the Apollo system.

Headquartered in Alameda, California, Penumbra has a significant global presence with operations in Europe and Asia Pacific. Its products are available in over 100 countries through direct sales and distributors.

Penumbra's brand reputation has been positively influenced by strong clinical trial results, particularly the STORM-PE trial. The pending acquisition by Boston Scientific Corporation also contributes to Penumbra's value and market trust. There is no specific information available detailing negative brand reputation events for Penumbra, Inc. within the past year.

Penumbra has a mixed ownership structure including institutional, retail, and individual investors. Approximately 88.88% of the stock is held by institutions, while insiders hold 4.20% of the stock. Public companies and individual investors own approximately 44.58% of the stock.